Highlights

  • Control Bionics completed US FDA registration and device listing for its NeuroStrip surface EMG wearable platform.
  • NeuroStrip’s FDA listing number is D605008, while its registration number is 3006789226.
  • The registration formally establishes NeuroStrip within the US regulatory framework for surface EMG medical devices.
  • Control Bionics said the credential may support discussions with clinical rehabilitation providers, medical researchers and medtech development partners.
  • The company is also pursuing TGA registration in Australia, CE marking in Europe and registration under the UK MDR framework.
  • NeuroStrip continues to target three principal application areas: performance, rehabilitation, and research and data.

Control Bionics Limited (ASX:CBL) has completed registration and device listing of its NeuroStrip surface electromyography wearable platform with the United States Food and Drug Administration, formally placing the product within the US medical device regulatory framework.

Control Bionics shares traded 4.62% higher at AUD 0.068 during the morning session on 4 August 2026 following the announcement. The stock remains up 70% over the past year. The positive share price movement came as the company outlined how the FDA registration may improve NeuroStrip’s standing in commercial discussions and support expansion into advanced rehabilitation, medical research and future human-computer interface applications.

Control Bionics Expands Its Neurotechnology Platform

Control Bionics is a neurotechnology company developing and commercialising non-invasive technology designed to capture and interpret physiological signals from the body.

Its platform measures electrical activity generated by muscles and converts those signals into data that can be used across several applications. The company said its technology is designed to provide medical-grade precision without requiring surgery or implantation.

The same underlying neural-signal platform supports four broad areas: performance, rehabilitation, research and data, and assistive communication.

Control Bionics has historically deployed its technology in assistive communication, where physiological signals can be used to support interaction by people with complex communication requirements. The company is now broadening the platform into sports performance, rehabilitation, medical research, technology partnerships and wider human-computer interface applications.

NeuroStrip forms part of that expansion strategy. It is a wearable surface EMG platform that records muscle-generated electrical activity and converts it into measurable information for performance, rehabilitation and research uses.

NeuroStrip Formally Enters US Medical Device Framework

The latest announcement confirms that NeuroStrip has been registered and listed with the FDA as a medical device.

The product has been assigned FDA listing number D605008 and registration number 3006789226.

This step formally recognises NeuroStrip within the United States regulatory framework governing surface electromyography devices.

Control Bionics described the registration as a meaningful credential that reinforces NeuroStrip’s status as a medical-grade platform. It also provides the product with recognised regulatory standing in one of the world’s largest healthcare markets.

The company was careful to distinguish registration and listing from the product’s existing commercial uses. NeuroStrip did not require this registration to continue operating in sports performance or general rehabilitation settings.

Instead, the company considers the FDA status particularly relevant to more advanced use cases where customers, research institutions or potential development partners may expect a recognised US medical device foundation before beginning formal engagement.

Advanced Clinical Applications Move Into Focus

The registration is expected to strengthen Control Bionics’ positioning with advanced clinical rehabilitation providers.

These organisations may use objective muscle-signal data to measure physical activity, monitor patient progress or support more informed rehabilitation decisions.

While the announcement does not disclose any new contracts or customer agreements, the company said recognised FDA status can carry importance in discussions with institutions operating under stricter clinical and procurement requirements.

NeuroStrip’s ability to capture surface EMG data may be relevant to rehabilitation settings where practitioners need measurable information about muscle activation and movement.

Control Bionics said the registration provides additional stature to the platform and may support deeper engagement across the rehabilitation sector.

The company continues to distinguish between everyday rehabilitation applications, where NeuroStrip is already able to operate, and more advanced clinical environments where formal regulatory recognition may be treated as a threshold requirement.

Medical Research and Data Opportunities Broaden

Another area highlighted in the announcement is medical research.

Research institutions often require devices used in clinical or human studies to have clearly documented regulatory status, particularly when studies involve medical applications or data that may support future product development.

Control Bionics believes the FDA registration can assist NeuroStrip’s positioning for research programs that require objective muscle-signal measurement.

The platform’s role is not limited to displaying muscle activity. Its technology is designed to capture physiological information and convert it into data that can be analysed and used in decision-making.

That capability aligns with the company’s research and data application area, one of the three main NeuroStrip verticals identified in the announcement.

The company did not provide a forecast for revenue or customer growth resulting from the registration. However, it said the regulatory milestone should support engagement with medical research institutions and potential partners evaluating NeuroStrip for new applications.

Human-Computer Interface Partnerships Represent a Longer-Term Opportunity

Control Bionics also identified future human-computer interface and medtech development partnerships as areas that may benefit from the US registration.

Human-computer interface technology involves translating physiological signals into commands, inputs or measurable digital outputs.

Because NeuroStrip measures electrical signals generated by muscles, the platform may be used as part of systems that connect physical activity with software, devices or other technology.

The company said potential development partners in these fields often expect a recognised regulatory foundation before entering detailed commercial or technical discussions.

The FDA listing therefore provides a formal credential that may reduce a barrier to engagement, although the announcement does not confirm any specific new partnership resulting from the registration.

Control Bionics is seeking to apply its established neural-signal capabilities beyond assistive communication into a broader range of scalable technology markets.

Sports Performance Rollout Remains Unaffected

NeuroStrip’s FDA registration does not change its ability to operate within sports performance settings.

The company explained that registration was not required for the product’s existing rollout in sports performance or general rehabilitation.

This distinction is important because the latest milestone relates mainly to the platform’s standing in more regulated or medically advanced environments rather than permission to begin selling into every market.

Within performance settings, surface EMG technology can provide data on muscle activation and movement. Control Bionics has positioned NeuroStrip as a platform capable of converting these signals into usable information.

The FDA registration adds a medical-device credential to the product but does not alter the company’s statement that NeuroStrip can continue being used in existing non-advanced clinical settings.

Control Bionics views the registration as supporting all three NeuroStrip application areas, even though its most direct commercial relevance may be in clinical rehabilitation, medical research and development partnerships.

Broader Global Regulatory Program Continues

The US registration forms part of a wider regulatory strategy covering several international markets.

Control Bionics has submitted an application for registration with Australia’s Therapeutic Goods Administration.

The company is also pursuing CE marking under the European Union Medical Device Regulation and registration under the United Kingdom Medical Devices Regulations framework.

These applications remain pending, and the company cautioned that there is no certainty regarding their timing or final outcome.

The announcement therefore confirms only the completed US FDA registration and listing. It does not indicate that Australian, European or UK approvals have been received.

Control Bionics considers the multiple applications important to scaling NeuroStrip into additional markets and increasing adoption with existing partners.

A broader regulatory footprint could provide a more consistent foundation for commercial discussions across international healthcare and research markets, although each application remains subject to the relevant regulatory process.

A Milestone Within a 25-Year Medtech History

Control Bionics linked the NeuroStrip registration to its more than 25 years of experience as a medtech business.

The company’s technology base was initially developed and deployed in assistive communication before being extended into new markets.

Its current strategy centres on using the same core capability to address several applications rather than building separate technologies for each vertical.

This platform model enables the company to apply objective muscle-signal measurement across performance, rehabilitation, research and data, and assistive communication.

Chief Executive Officer and Managing Director Jeremy Steele described the FDA registration as an important credential for NeuroStrip and Control Bionics.

He said the product already supported sports performance and everyday rehabilitation without requiring this regulatory status, but formal recognition under the US framework improved the company’s positioning in advanced clinical and research settings.

The company also views the milestone as supporting future engagement with human-computer interface and medtech partners that may require recognised regulatory status before progressing discussions.

What the FDA Registration Does and Does Not Mean

The update is favourable because NeuroStrip has completed a formal US registration and device listing process and now has a recognised place within the FDA medical device framework.

However, investors should distinguish registration and listing from terms such as FDA approval or FDA clearance, which were not used in the company’s announcement.

Control Bionics stated that the product is registered and listed as a medical device. The announcement does not indicate that NeuroStrip underwent a separate premarket approval process or received a new marketing clearance.

The practical value identified by the company relates to credibility, regulatory standing and the ability to engage with customers or partners that expect a US medical device registration.

The announcement also does not provide revenue guidance, contract values, sales forecasts or a timetable for commercial outcomes linked to the registration.

Its immediate significance lies in formalising NeuroStrip’s regulatory status and supporting the company’s broader commercial and international regulatory strategy.

Three NeuroStrip Markets Shape the Growth Plan

Control Bionics is targeting growth across three core NeuroStrip application areas: performance, rehabilitation, and research and data.

Performance applications focus on the use of muscle-signal information in sporting or physical activity environments.

Rehabilitation applications range from everyday use to more advanced clinical settings, where the FDA registration may carry greater relevance.

Research and data applications involve capturing, analysing and applying physiological information in medical research or product development programs.

The company believes recognised US status can support all three areas by improving the platform’s standing with existing and prospective customers.

The registration may be especially useful where organisations have formal medical-device procurement, compliance or research requirements.

Control Bionics intends to continue scaling NeuroStrip into additional markets while seeking greater adoption among current partners.

Further Regulatory Outcomes Remain Pending

The next regulatory developments are expected to relate to the company’s applications in Australia, Europe and the United Kingdom.

Control Bionics has not provided definite completion dates for these processes.

The company’s forward-looking statement notes that regulatory applications are subject to uncertainty and that actual outcomes may differ from current expectations.

As a result, the FDA registration is a completed milestone, while the TGA, CE and UK MDR processes should be treated as pending applications.

Future announcements may provide updates on timing, requests for additional information or final regulatory outcomes.

For now, the company’s completed US registration gives NeuroStrip a recognised status in the US medical device market while the broader international program continues.

What the Update Means for Control Bionics

The latest development adds a formal regulatory credential to a platform already being positioned across multiple commercial and clinical markets.

The registration does not by itself confirm new revenue, customer contracts or regulatory outcomes in other regions.

Its importance, based on the company’s explanation, is that it may improve NeuroStrip’s credibility and support engagement with organisations that require recognised US medical-device status.

The update is therefore positive in relation to regulatory positioning and market access discussions, particularly across advanced rehabilitation, research and medtech partnerships.

Control Bionics must still convert that improved positioning into customer adoption, partnerships and financial outcomes.

The company is also awaiting the outcome of separate regulatory applications in Australia, Europe and the United Kingdom.

Conclusion

Control Bionics has completed FDA registration and device listing for NeuroStrip, formally establishing the surface EMG wearable platform within the United States medical device framework.

The platform has received listing number D605008 and registration number 3006789226.

The company said the registration was not required for NeuroStrip’s existing sports performance and general rehabilitation use. Instead, it is expected to be more relevant in advanced clinical rehabilitation, medical research and potential human-computer interface or medtech partnerships where recognised regulatory status may be required.

Control Bionics is also seeking TGA registration, CE marking and UK MDR registration, although the timing and outcomes of those applications remain uncertain.

The latest milestone supports the company’s plan to expand NeuroStrip across performance, rehabilitation, and research and data markets while building on its established neurotechnology and assistive communication experience.